Pirfenidone Tablet, Coated
Product Images NDC 72162-2465

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Pirfenidone (NDC 72162-2465). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622465)

This is a description for a medication called Pirfenidone. Each film-coated tablet contains 267 mg of Pirfenidone. The usual dosage information can be accessed by scanning the package insert QR code. The tablets should be stored at 25°C (77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). There are 270 tablets in the package (3 bottles of 90 tablets each). The medication is labeled by Bryant Ranch Prepack, Inc. and manufactured by Alembic Pharmaceuticals Limited. Keep out of reach of children.*

FDA Label Image

Figure 1 (Pirfenidone Figure1)

This text provides data on the percentage of patients with worsened, no change, or improved %FVC (Forced Vital Capacity) after treatment with Pirfenidone compared to Placebo. It shows the absolute change in %FVC from baseline to week 52 for patients in the study. The results indicate the number of patients in each category for different %FVC ranges.*

FDA Label Image

Figure 2 (Pirfenidone Figure2)

This is a comparison of the mean change in Forced Vital Capacity (FVC) in milliliters over different weeks between patients treated with Pifrenidone (n=278) and patients on placebo (n=277). The chart shows a steady decline in FVC for both groups over the weeks.*

FDA Label Image

Figure 3 (Pirfenidone Figure3)

This information is a comparison of the percentage of patients alive between Pirfenidone and Placebo over time. The data displays a hazard ratio of 0.75 (95% CI: 0.51 to 1.11) for Pirfenidone compared to Placebo. The survival rates are visualized over weeks with the number of patients at risk indicated for each time point. This data can help in evaluating the efficacy of Pirfenidone in patient survival compared to Placebo.*

FDA Label Image

Pirfenidone-pi-table1 (Pirfenidone Pi Table 1)

This text provides a dosing schedule for Pirfenidone tablets in 267 mg strength. The schedule outlines the number of tablets to be taken in the morning, afternoon, and evening for each day in weeks 1-7, weeks 8-14, and onwards from day 15. The total number of pills to be taken each day is also specified for the respective time periods.*

FDA Label Image

Pirfenidone-pi-table-2 (Pirfenidone Pi Table 2)

This is a dosing schedule for Pirfenidone tablets 801 mg, where the recommended dosage is 1 tablet in the morning, 1 tablet at lunchtime, and 1 tablet in the evening, totaling 3 pills per day from day 15 onwards.*

FDA Label Image

Pirfenidone (Pirfenidone Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.